Form D · Biotechnology
ALLOZYNE INC
Seattle, WA · CIK 0001345630
Offering snapshot reported Aug 16, 2013 · SEC filing
- Reported sold
- $2.45M Offering amount: $3.55M
- Investors reported
- 10 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 22, 2013 As reported in this filing
Fundraising history
Reported soldDates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.
What changed?
Latest filing versus its linked predecessor, where available.
- Reported sold$900,000 → $2,452,450
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 16, 2013 | Amendment | $2,452,450 | $1,552,450vs Apr 5, 2013 | 10 | SEC filing |
| Apr 5, 2013 | Initial | $900,000 | No comparison | 10 | SEC filing |
| Jun 1, 2012 | Initial | $2,002,000 | No comparison | 5 | SEC filing |
| May 18, 2012 | Initial | $0 | No comparison | 11 | SEC filing |
| Feb 3, 2012 | Initial | $2,502,500 | No comparison | 5 | SEC filing |
| Nov 9, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
| May 7, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Nov 22, 2005 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Sep 13, 2005 | Paper | Not reported | No comparison | Not reported |
Offering details
- Securities
- Debt, Option to acquire, Security to be acquired
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-194545
Includes price of warrants
Source: Form D, filed Aug 16, 2013. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| John Bencich | Executive |
| Meenu Chhabra | Director, Executive |
| Steven Gillis | Director |
| Kenneth Grabstein | Executive |
| Michael Steinmetz | Director |
| David Tirrell | Director |
| Carl Weissman | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1600 Fairview Ave East Suite 300
Seattle, WA, 98102
Seattle, WA, 98102